Enoblituzumab clinical trials
Also written MGA271.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses Enoblituzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
MacroGenics (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · TJ Biopharma Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses Enoblituzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate CancerActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT02923180Written as EnoblituzumabHow we know
- Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate CancerActive, not recruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06014255Written as EnoblituzumabHow we know
- Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedPhase 1MacroGenicsNCT02475213Written as Enoblituzumab Schedule 1How we know
- Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid TumorsWithdrawnPhase 2TJ Biopharma Co., Ltd.NCT05338580Written as TJ271 Injection in Combination with PembrolizumabHow we know
- Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid TumorsCompletedPhase 1MacroGenicsNCT02982941Written as EnoblituzumabHow we know
- Safety Study of MGA271 in Refractory CancerCompletedPhase 1MacroGenicsNCT01391143Written as MGA271How we know
- Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerCompletedPhase 1MacroGenicsNCT02381314Written as enoblituzumab plus ipilimumabHow we know
- Tissue Procurement Substudy for Participants in Study CP-MGA271-01TerminatedPhase 1MacroGenicsNCT01918930Written as MGA271How we know
Given beside what is tested · 4 — Enoblituzumab is usual care or a partner of the new treatment
- MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerTerminatedPhase 1Masonic Cancer Center, University of MinnesotaNCT05708924Written as EnoblituzumabHow we know
- Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck CancerTerminatedPhase 2MacroGenicsNCT04634825Written as EnoblituzumabHow we know
- FT516 and IL2 With Enoblituzumab for Ovarian CancerCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT04630769Written as EnoblituzumabHow we know
- Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckWithdrawnPhase 2/3MacroGenicsNCT04129320Written as enoblituzumabHow we know
Codes
What other systems call Enoblituzumab · ClinicalTrials.gg INT017247
- UNII (FDA) M6030H73N9ENOBLITUZUMABConfirmed FDA, Wikidata
- Wikidata Q19904073EnoblituzumabConfirmed FDA, Wikidata
- NCI Thesaurus C97510EnoblituzumabOne source FDA
- DrugBank DB15017One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | M6030H73N9 | ENOBLITUZUMAB | Confirmed FDA, Wikidata |
| Wikidata | Q19904073 | Enoblituzumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C97510 | Enoblituzumab | One source FDA |
| DrugBank | DB15017 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.